Results 281 to 290 of about 332,877 (319)

[Practical concepts of catheter-directed aspiration thrombectomy in ECMO-supported patients]. [PDF]

open access: yesREC Interv Cardiol
Tébar-Márquez D   +5 more
europepmc   +1 more source

Discovery of a Potent and Selective TEAD Degrader with Durable Degradation Activity

open access: yesAdvanced Science, EarlyView.
KG‐FP‐003, a highly potent TEAD‐YAP PROTAC derived from the patented inhibitor is developed. It selectively degrades endogenous TEAD proteins in HiBiT systems without IMiD‐related off‐target effects. Screening across 867 cancer cell lines revealed broad and superior anti‐tumor activity, highlighting its therapeutic potential through targeted TEAD ...
Linhui Cao   +25 more
wiley   +1 more source

Prickle4 Drives Microenvironmental Remodeling and Resistance to Parp Inhibition in IDH‐Mutant Glioma

open access: yesAdvanced Science, EarlyView.
IDH‐mutant gliomas exhibit sensitivity to PARP inhibitors (PARPi) owing to oncometabolite 2‐HG‐induced DNA repair defects. PARPi treatment induces resistance by upregulating Prickle4, which promotes VEGF‐driven angiogenesis. Combining PARPi veliparib with anti‐angiogenic lenvatinib blocks this pathway, causing tumor regression and prolonged survival in
Ju Yang   +16 more
wiley   +1 more source

What does Colombia require to earn a Nobel Prize in Medicine? [PDF]

open access: yesColomb Med (Cali)
Palacios Gómez M, Porras Zapata DY.
europepmc   +1 more source

Continuous Suppression of Pathological Retinal and Choroidal Neovascularization in Cynomolgus Monkeys via Noninvasive Ophthalmic Delivery of a Novel Anti‐VEGFA Nanobody and Proprietary Penetratin Analog Formulation

open access: yesAdvanced Science, EarlyView.
Pathological retinal/choroidal neovascularization drives vision loss in DR and AMD. Current anti‐VEGF injections, while effective, require invasive, frequent administration. Pene/LQ015, is developed a novel topical anti‐VEGFA nanobody formulation achieving therapeutic intraocular levels through penetratin analog‐enhanced delivery.
Chong Chen   +12 more
wiley   +1 more source

Interactions of Antibody Drug Conjugate Anti‐Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate Immunotherapy

open access: yesAdvanced Science, EarlyView.
Antibody drug conjugates deliver their cytotoxic anti‐tubulin or topoisomerase I inhibitor payloads to tumors through cancer cell receptor targeting. The released drug payloads induce cellular changes that interact with radiotherapy resulting in radiosensitization that improves cancer cell kill and stimulates anti‐tumor immune responses.
Jacqueline Lesperance   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy